Education
About Us
Working with TipRanks
Follow Us
LENZ Therapeutics (LENZ)
NASDAQ:LENZ
LENZ Stock Chart & Stats
$22.96
-$0.43(-1.58%)
At close: 4:00 PM EST
$22.96
-$0.43(-1.58%)
Day’s Range― - ―
52-Week Range$16.54 - $50.40
Previous CloseN/A
Volume24.39K
Average Volume (3M)1.19M
Market Cap
$612.37M
Enterprise Value$1.13B
Total Cash (Recent Filing)$202.17M
Total Debt (Recent Filing)$461.00K
Price to Earnings (P/E)―
Beta1.10
Next Earnings
Mar 25, 2026EPS Estimate
-0.95Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding28,522,097
10 Day Avg. Volume1,321,540
30 Day Avg. Volume1,188,087
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)3.01
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap1.84
Enterprise Value/Revenue64.23
Enterprise Value/Gross Profit225.78
Enterprise Value/Ebitda-16.64
Forecast
1Y Price Target
$57.60Price Target Upside150.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-2.59
Revenue Forecast (FY)$12.90M
Bulls Say, Bears Say
Bulls Say
FDA ApprovalVIZZ was approved by the FDA on July 31 and became commercially available at the start of October, with broad commercial availability expected by mid-November.
Marketing CampaignThere is enthusiasm about the prospective near-term impacts from starting the discussed DTC campaign featuring Sarah Jessica Parker, which is believed to generate public buzz for the novel VIZZ product.
Product EfficacyVIZZ demonstrates a significant efficacy profile with 91% of patients improving near vision by at least two lines within 30 minutes, without compromising distance vision.
Bears Say
Investor ConcernsThere is apprehension among some investors around the launch, with a show-me component to seeing the first few quarters of success.
Stock Price DeclineShares are currently down 9%, which presents an attractive buying opportunity.
LENZ Therapeutics News
LENZ FAQ
What was LENZ Therapeutics’s price range in the past 12 months?
LENZ Therapeutics lowest stock price was $16.54 and its highest was $50.40 in the past 12 months.
What is LENZ Therapeutics’s market cap?
LENZ Therapeutics’s market cap is $612.37M.
When is LENZ Therapeutics’s upcoming earnings report date?
LENZ Therapeutics’s upcoming earnings report date is Mar 25, 2026 which is in 137 days.
How were LENZ Therapeutics’s earnings last quarter?
LENZ Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.692 by $0.102.
Is LENZ Therapeutics overvalued?
According to Wall Street analysts LENZ Therapeutics’s price is currently Undervalued.
Does LENZ Therapeutics pay dividends?
LENZ Therapeutics pays a Weekly dividend of $7.21 which represents an annual dividend yield of N/A. See more information on LENZ Therapeutics dividends here
What is LENZ Therapeutics’s EPS estimate?
LENZ Therapeutics’s EPS estimate is -0.95.
How many shares outstanding does LENZ Therapeutics have?
LENZ Therapeutics has 28,522,097 shares outstanding.
What happened to LENZ Therapeutics’s price movement after its last earnings report?
LENZ Therapeutics reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.692. Following the earnings report the stock price went down -23.458%.
Which hedge fund is a major shareholder of LENZ Therapeutics?
Currently, no hedge funds are holding shares in LENZ
LENZ Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$57.60 (150.87% Upside)
$57.60 (150.87% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $33.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.76%
12-Months-Change
Fundamentals
Return on Equity
-28.78%
Trailing 12-Months
Asset Growth
-5.94%
Trailing 12-Months
Company Description
LENZ Therapeutics
LENZ Therapeutics (LENZ) is a biopharmaceutical company focused on developing innovative treatments for eye diseases. The company operates in the healthcare sector, specifically targeting ophthalmology, with a primary emphasis on developing therapies for presbyopia and other vision-related disorders. LENZ leverages cutting-edge science and technology to create novel therapeutics that address unmet medical needs in the field of eye care.
LENZ Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for LENZ, highlighted by the successful early launch of VIZZ and significant financial backing. While there were minor issues with transient side effects and initial retail availability, the overall sentiment was bolstered by strong prescription metrics, high awareness among doctors, and strategic partnerships.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$57.60
▲(150.87% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Stoke Therapeutics
―
CureVac
―
Tourmaline Bio
―
Rapport Therapeutics, Inc.
―
Ownership Overview
16.91% Insiders
0.49% Mutual Funds
0.08% Other Institutional Investors
74.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---